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Abstract   
 
Primary cardiac lymphoma is extremely rare. We present a case of 70-year old man with 
primary cardiac lymphoma involving interatrial septum, presenting as atrial flutter and total 
heart block. The diagnosis was obtained by echocardiography guided transvenous 
endocardial biopsy which revealed diffuse large B-cell non-Hodgkin lymphoma, CD 20 +. 
After six courses of immunochemotherapy the patient achieved a complete remission. After 
two months he developed a series of epileptic attacks. Intracerebral lymphoma extension 
was diagnosed. Two cycles of high dose of methotrexate and cranial irradiation were applied 
resulting in a second complete remission. 
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Introduction 
Primary cardiac lymphoma (PCL) is a non-Hodgkin lymphoma (NHL) confined to the heart or 
pericardium or NHL in which the bulk of the tumor is located in the heart (1, 2). PCL is 
extremely rare; it represents 1.3% of all primary cardiac tumors, 1% of all lymphomas and 
0.5% of extranodal lymphomas. It occurs more commonly in immunocompromised patients, 
particularly in association with human immunodeficiency virus infection. Usual presenting 
symptoms are chest pain, congestive heart failure, pericardial effusions and arrhythmias. 
Although occasionally successful in establishing the diagnosis, pericardial or pleural fluid 
evaluation alone can lead to misdiagnosis. Diagnostic cytologic samples were obtained in 
only 67% of patients with a PCL (3). Biopsy of cardiac tissue is mandatory because 75% of 
all myocardial tumors are benign. The prognosis is generally poor but prolonged survival has 
been reported after chemotherapy. Chemoterapy is the only effective treatment of PCL. 
Standard therapy protocols are CHOP (cyclophosphamide, doxorubicin, vincristine and 
prednisone) or CNOP (mitoxantrone instead of doxorubicin) (2, 4). Radical surgery is 
discouraged.    
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Case report 
A 70-year-old immunocompetent man with chronic hepatitis B was transferred to our 
institution from another hospital because of atrial flutter and total heart block. He was 
addmited to the other hospital because of a 3-month history of low grade fever and 
arthralgias. No infective cause was diagnosed. On admission his temperature was 37.6 C, 
blood pressure 160/85 mmHg, heart rate 50 bpm, lungs were clear on auscultation, cardiac 
examination revealed normal heart sounds without murmurs, gallops or rubs. ESR was 
accelerated, CBC showed normocytic anemia, LDH and CRP were elevated. Transaminases 
were mildy elevated. ECG indicated atrial flutter with episodes of total AV block. 
Transthoracic echocardiography (TTE) revealed a signal intense mass at the atrial septum 
(figure 1). Transesophageal echocardiography (TEE) confirmed the presents of an avascular 
tumor measuring 5.2x2.5 cm involving interatrial septum, bases of mitral and tricuspid valves 
and aortic root (figure 2). The valves were morphologically and functionally normal. Thoracic 
and abdominal CT scan revealed a tumorous mass originating from the interatrial septum 
and expanding between mediastinal great vessels. Maximal mediastinal tumorous mass 
diameter was 3.6 cm while mediastinal lymph nodes were only mildly enlarged, measuring 
1.8 cm in their greatest diameter. Peripheral and infradiaphragmatic lymph nodes were not 
enlarged. TTE guided transvenous endocardial biopsy revealed a diffuse large B-cell NHL, 
CD 20 +. Bone marrow biopsy was unremarkable. Immunochemotherapy with rituximab 
(genetically engineered anti-CD20 antibody), cyclophosphamide, doxorubicin, vincristine and 
prednisone (R-CHOP) was given. TTE after three days showed significant tumor regression. 
TTE and CT scan after three cycles showed no signs of tumor but a reduction of left 
ventricular ejection fraction (LVEF) to 45-50%. The cardiotoxic drug doxorubicin was 
switched to the less cardiotoxic mitoxantrone and three more cycles of R-CNOP were 
applied. Therapy was complicated with pneumonia and febrile neutropenia despite G-CSF 
prophylaxis. Evaluation after six courses of treatment confirmed the complete remission. Mild 
LVEF reduction and atrial flutter persisted, there were no signs of total AV block. Two weeks 
later the patient was admitted because of epileptic attacks. Brain CT scanning showed a left 
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frontal tumor mass consistent with intracerebral extension of lymphoma. He received two 
cycles of high-dose methotrexate and cranial irradiation resulting in a second complete 
remission.  Eighteen months after diagnosis and 11 months after the end of treatment the 
patient remains in complete remission with moderate encephalopathy.    
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Discussion 
Atrial flutter and complete heart block are uncommon presentations of PCL. The rarity and 
heterogeneous clinical presentation of PCL make the diagnosis difficult so that it is frequently 
not made during lifetime of the patient. In our case the diagnosis was established and 
treatment started within three months after the onset of symptoms, while the patient was still 
in relatively favorable clinical condition. We believe that his lymphoma was of primary cardiac 
origin because the bulk of the tumor was located in the heart and it had peculiar extension 
pattern which followed the great vessels, instead of the usual mediastinal nodal spread. 
Although fever, increased ESR, CRP, LDH and anaemia point to a more diffuse disease the 
patient had also chronic hepatitis B with permanent elevation of liver transaminases. We 
believe that mild mediastinal lymphadenopathy was secondary to intrathoracic propagation of 
primary cardiac lymphoma. Since the biopsy of the atrial septum carries a much higher risk 
of cardiac perforation than the biopsy of the left ventricle, the procedure was performed in the 
cardiac catheterization laboratory under simultaneous echocardiography guidance. The first 
cycle of chemotherapy must be given with caution because of a high risk of cardiac rupture 
during rapid tumor regression (5). Intracranial progression of PCL, as seen in our patient, 
seems quite frequent. This can be explained by the seeding of lymphoma cells from 
intracardiac or intravascular tumor parts. Since drugs used commonly for first-line treatment 
of lymphoma do not penetrate the blood-brain barrier, an intracerebral relapse should not be 
interpreted as indicating chemorefractoriness of the tumor. Indeed, our patient responded 
favorably to high-dose methotrexate and brain irradiation, modalities used for treating 
primary cerebral lymphomas (6). Unfortunately, he developed encephalopathy, a common 
complication of brain irradiation in his age group.  
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Figure legends  
 
Figure 1. TTE (apical four chamber view) demonstrates PCL in interatrial septum.  
LA indicates left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle. 
 
 
Figure 2. TEE demonstrates PCL in interatrial septum.  
LA indicates left atrium; LV, left ventricle; RA, right atrium. 
 
